Mauritius vs Turkmenistan: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Mauritius
98.0%
in 2025
Turkmenistan
98.0%
in 2025
Mauritius rank
11th
Turkmenistan rank
11th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Mauritius
- Turkmenistan
How they compare
Mauritius currently reports 98.0% against 98.0% in Turkmenistan, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Turkmenistan ahead.
Mauritius ranks 11th and Turkmenistan ranks 11th of 194 countries.
Mauritius has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Mauritius | Turkmenistan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 28.7% | 0.0% | 28.7% | Mauritius |
| 2020s | 95.0% | 85.7% | 9.3% | Mauritius |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Mauritius or Turkmenistan?
- Mauritius, at 98.0% against 98.0% in Turkmenistan as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Mauritius and Turkmenistan?
- 0.0%, with Mauritius ahead.
- How many years of comparable data are there for Mauritius and Turkmenistan?
- 18 years are reported by both, from 2008 to 2025.
- How do Mauritius and Turkmenistan rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Mauritius ranks 11th and Turkmenistan ranks 11th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.